Arteriosclerosis Thrombosis and Vascular Biology

Arteriosclerosis, Thrombosis, and Vascular Biology is a monthly peer-reviewed journal of the American Heart Association, published for its Council on Arteriosclerosis, Thrombosis and Vascular Biology and distributed by Wolters Kluwer, founded in 1981 as Arteriosclerosis and carrying a 2025 Journal Impact Factor of 8.8《动脉硬化、血栓和血管生物学》（Arteriosclerosis Thrombosis and Vascular Biology）是美国心脏协会（American Heart Association）旗下动脉硬化、血栓形成与血管生物学理事会的月刊同行评审期刊，由（Wolters Kluwer）发行，1981 年以（Arteriosclerosis）之名创刊，2025 年影响因子为 8.8。

Scope

• ATVB publishes laboratory-based, translational, clinical and population research on the biology, prevention and impact of vascular diseases related to arteriosclerosis and thrombosis该刊发表以实验室、转化、临床与人群为基础的血管疾病研究，主题是与动脉硬化及血栓相关的血管疾病的生物学、预防与影响。
• Contributions come from a broad range of disciplines, including biochemistry, biophysics, cell and molecular biology, clinical investigation, epidemiology, genetics, lipoproteins, nutrition, metabolism and pathology其稿源横跨多个学科，包括生物化学、生物物理学、细胞与分子生物学、临床研究、流行病学、遗传学、脂蛋白、营养学、代谢与病理学。
• The research it reports runs from basic discovery through translational and clinical work to population-based investigation, and its most cited papers have dealt with atherosclerotic lesion classification, adiponectin, carotid plaque shear stress and endothelial dysfunction该刊报道的研究自基础发现延伸至转化、临床与人群研究，其被引最多的论文涉及动脉粥样硬化病变分型、脂联素、颈动脉斑块剪切应力与内皮功能障碍。^[1]
• Editorial content includes Original Research, Reviews, the themed review series ATVB in Focus, Editorial Commentaries and eLetters其编辑内容涵盖原创研究、综述、专题综述系列（ATVB in Focus）、编辑评论与快评（eLetters）。
• Under its current editor the journal has broadened its interest areas to take in metabolism, bioengineering, inter-organ cross-talk and the control of gene transcription在现任主编任内，该刊把关注领域拓展至代谢、生物工程、器官间交互与基因转录调控。
• Recurring themes include atherosclerosis and plaque biology, lipoprotein and adipokine metabolism, vascular inflammation, thrombosis and hemostasis, arterial stiffness and vascular ageing, and valvular and peripheral arterial disease反复出现的主题包括动脉粥样硬化与斑块生物学、脂蛋白与脂肪因子代谢、血管炎症、血栓与止血、动脉僵硬度与血管老化以及瓣膜与外周动脉疾病。
• The journal is indexed in the Science Citation Index Expanded and MEDLINE, and in the 2025 Journal Citation Reports it is in the first quartile both in peripheral vascular disease, at 8th of 100 titles, and in hematology该刊被（SCIE）与（MEDLINE）收录，在 2025 年期刊引证报告中于外周血管病类位居第一四分位、于 100 种刊中排名第 8，在血液学类亦为第一四分位。

History

• The journal began in January 1981 as Arteriosclerosis, a bimonthly publication of the American Heart Association, with Edward Bierman of the University of Washington as its first editor该刊于 1981 年 1 月以（Arteriosclerosis）创刊，是美国心脏协会的双月刊，首任主编为（University of Washington）的（Edward Bierman）。^[2]
• Its first editorial team consisted of Edward Bierman's University of Washington colleagues Paul Bornstein, Laurence Harker, Arno Motulsky and Russell Ross, and a European editor, Goran Bondjers of the University of Gothenburg, joined in 1988首届编辑团队由（Edward Bierman）在（University of Washington）的同事（Paul Bornstein）、（Laurence Harker）、（Arno Motulsky）与（Russell Ross）组成，1988 年又增设欧洲编辑（Goran Bondjers），来自（University of Gothenburg）。
• The name became Arteriosclerosis and Thrombosis in 1991 and the present title in January 1995, with volume numbering running unbroken from 1981刊名于 1991 年改为（Arteriosclerosis and Thrombosis），1995 年 1 月起改用现名，卷号自 1981 年起连续编号。
• Under the editor Alan Fogelman the journal moved to monthly publication in January 1992, and the team later added an Asian editorial office led by Akira Takeshita of Kyushu University alongside the European office在主编（Alan Fogelman）主持下，该刊于 1992 年 1 月改为月刊；其编辑团队其后在原有的欧洲编辑部之外增设亚洲编辑部，由（Kyushu University）的（Akira Takeshita）负责。
• The journal switched to a web-based submission and review system with open access options, and it appointed a technical editor to strengthen the analysis and reproducibility of published work该刊改用基于网络的投稿与评审系统并提供开放获取选项，并设立技术编辑一职，以加强已发表研究的数据分析与可重复性。
• It has been distributed by Lippincott Williams & Wilkins on behalf of the American Heart Association since 1998自 1998 年起，该刊由（Lippincott Williams & Wilkins）代表美国心脏协会发行。
• Its Journal Impact Factor moved from 8.311 in 2021 and 10.514 in 2022 to 7.4 in 2024 and 8.8 in 2025其影响因子由 2021 年的 8.311 与 2022 年的 10.514，变为 2024 年的 7.4 与 2025 年的 8.8。

Editors

• Ann Marie Schmidt of NYU Grossman School of Medicine, director of the Diabetes Research Program at NYU Langone Health, became editor-in-chief on 1 July 2022 and works on receptors for advanced glycation end products, diabetes and cardiovascular-metabolic disease主编（Ann Marie Schmidt）为（NYU Grossman School of Medicine）教授、（NYU Langone Health）糖尿病研究项目主任，2022 年 7 月 1 日就任，研究晚期糖基化终末产物受体、糖尿病与心血管代谢疾病。
• She succeeded Alan Daugherty of the University of Kentucky, who led the journal from 2012 to 2022 and strengthened its quality control and statistical review她接替（University of Kentucky）的（Alan Daugherty）；后者自 2012 年至 2022 年任主编，强化了刊物质量控制与统计审查。
• Earlier editors-in-chief were Edward Bierman from 1981, Alan Fogelman from 1991, Donald Heistad from 1999, Mark Taubman from 2007 and Edward Fisher from 2011更早的主编依次为 1981 年起的（Edward Bierman）、1991 年起的（Alan Fogelman）、1999 年起的（Donald Heistad）、2007 年起的（Mark Taubman）与 2011 年起的（Edward Fisher）。
• The editorial team includes deputy, senior, associate and review editors together with a technical editor, and its membership is deliberately international其编辑团队由副编辑、资深编辑、协理编辑与评审编辑组成，另设技术编辑，成员刻意保持国际化的国别构成。
• Manuscripts are submitted and reviewed through a web-based system run by the publisher, and the journal is peer reviewed稿件经出版方运营的网络系统投稿与评审，该刊实行同行评审。
• The journal works closely with the American Heart Association's Council on Arteriosclerosis, Thrombosis and Vascular Biology, including its annual Vascular Discovery scientific sessions, and promotes early-career investigators through the Daniel Steinberg, Karl Link and Werner Risau awards该刊与美国心脏协会动脉硬化、血栓形成与血管生物学理事会紧密协作，包括其年度（Vascular Discovery）学术会议，并通过（Daniel Steinberg）奖、（Karl Link）奖与（Werner Risau）奖扶持青年研究者。